SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure

Sarepta Therapeutics (SRPT) reported a Q3 adjusted loss of $0.13 per share, missing analyst estimates, with revenue down 15% year-over-year to $399.4 million, though still exceeding consensus. The company's stock plunged over 35% pre-market after its Phase III ESSENCE study for Amondys 45 and Vyondys 53 failed to achieve statistical significance on its primary endpoint, jeopardizing the conversion of their accelerated FDA approvals to traditional ones. This setback, coupled with a 27% decline in Elevidys sales due to suspended shipments to non-ambulatory patients following safety concerns and patient deaths, has led to FDA discussions on revised safety labeling and a strategic shift towards siRNA programs.

Analysis

Sarepta Therapeutics (SRPT) reported an adjusted Q3 loss of $0.13 per share, significantly missing the Zacks Consensus Estimate of $0.01 EPS and reversing last year's profit. Total revenue declined 15% year-over-year to $399.4 million, primarily driven by a 27% drop in Elevidys sales to $131.5 million, although both metrics still surpassed consensus estimates. The company's stock plunged over 35% pre-market following these announcements, reflecting significant investor concern.

The Phase III ESSENCE study for Amondys 45 and Vyondys 53 failed to achieve statistical significance on its primary endpoint, despite positive numerical trends. This outcome is critical as the study was intended to convert the therapies' accelerated FDA approvals into traditional ones, raising substantial questions about the regulatory path and commercial outlook for Sarepta's PMO therapy franchise. The stock has already seen an 80% year-to-date decline, underscoring market anxiety.

Elevidys sales were further impacted by the voluntary suspension of shipments to non-ambulatory patients in June 2025, prompted by safety concerns and three patient deaths linked to acute liver failure. Sarepta is currently in discussions with the FDA to finalize safety labeling, which may include removing the non-ambulatory indication and adding a box warning. This has led to a strategic pivot, with the company pausing most of its LGMD pipeline to focus on siRNA programs acquired from Arrowhead Pharmaceuticals, with initial data anticipated in early 2026.

Despite these setbacks, Sarepta maintains guidance of at least $500 million in annual Elevidys revenue from the ambulant population for full-year 2025 and $900 million from its PMO therapies. However, the significant regulatory hurdles, safety concerns, and the need for successful pipeline execution introduce considerable uncertainty into these projections and the company's future growth trajectory.

Key Decisions for Investors

• Investors should closely monitor the outcome of Sarepta's discussions with the FDA regarding the traditional approval path for Amondys 45 and Vyondys 53, as well as the revised safety labeling for Elevidys, given their critical impact on revenue streams.
• Evaluate the potential and execution of Sarepta's newly prioritized siRNA pipeline, particularly the programs acquired from Arrowhead, as successful development and initial data in early 2026 will be crucial for long-term value creation and diversification.
• Reassess SRPT's valuation and risk profile in light of the significant regulatory and commercial challenges facing its key DMD therapies, the ongoing safety concerns, and the substantial year-to-date stock depreciation.